Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Povetacicept (ALPN-303), a Potent Dual BAFF/APRIL Antagonist in Development for the Treatment of Autoimmune Cytopenias, Suppresses Disease in a Mouse Model of Autoimmune Hemolytic Anemia

Katherine E. Lewis, Luana Griffin, Zahra Maria, Amanda Enstrom, Armand R. Bankhead, III, Stanford L. Peng, Stacey R. Dillon

Blood (2023) 142 (Supplement 1): 6462.

https://doi.org/10.1182/blood-2023-177786

Published: 2023

Journal Articles

A Randomized, Placebo-Controlled, Phase 1 Study in Healthy Adult Volunteers of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN303, a Potent Dual BAFF/APRIL Antagonist for the Treatment of Autoimmune Cytopenias

Stacey R. Dillon, Rupert Davies, Jason D. Lickliter, Kristi L. Manjarrez, Alina Smith, Mary C. Lessig, Lori Blanchfield, Russell J. Sanderson, Allison Chunyk, Tiffany Blair, Amanda Enstrom, Hany Zayed, Stanford L. Peng

Blood (2022) 140 (Supplement 1): 8401–8403.

https://doi.org/10.1182/blood-2022-155908

Published: 2022

Journal Articles

An Open Label Study of Alpn-101, a First-in-Class Dual CD28/ICOS Antagonist, in Subjects with Steroid-Resistant or Steroid-Refractory Acute Graft Versus Host Disease (aGVHD)

Jing Yang, PhD, Jan L. Hillson, MD, Kristi L. Manjarrez, Jennifer R. Wiley, DRSc, Gary D. Means, PhD, Stacey R. Dillon, PhD, Stanford L. Peng, MD,PhD

Blood (2019) 134 (Supplement_1): 372.

https://doi.org/10.1182/blood-2019-126034

Published: 2019

Journal Articles

Therapeutic Candidate Alpn-101, a Dual ICOS/CD28 Antagonist, Potently Suppresses Human/NSG Mouse Xenograft Graft Vs. Host Disease (GvHD) in a Dose Ranging Study and Reduces Disease Activity in a Mouse Model of Hemophagocytic Lymphohistiocytosis (HLH)

Stacey R. Dillon, PhD, Katherine E. Lewis, PhD, Katherine Verbist, PhD, Paige Tedrick, PhD, Sabrin Albeituni, PhD, Ryan Swanson, B.S., Lawrence S. Evans, B.S., Steven D Levin, PhD, Mark W. Rixon, PhD, Stanford L. Peng, MD, PhD, Kim E. Nichols, MD, Kristine M. Swiderek, PhD

Blood (2018) 132 (Supplement 1): 2037.

https://doi.org/10.1182/blood-2018-99-110001

Published: 2018

Journal Articles

Novel Variant Ig Domain (vIgD) Proteins Generated Via Directed Evolution of Igsf Domains Have Therapeutic Efficacy in Animal Models of Graft Versus Host Disease

Steven D Levin, PhD, Lawrence S. Evans, Erika Rickel, Martin F. Wolfson, Stacey R. Dillon, PhD, Michael G. Kornacker, PhD, Ryan Swanson, Stanford L. Peng, MDPhD

Blood (2017) 130 (Supplement 1): 1892.

https://doi.org/10.1182/blood.V130.Suppl_1.1892.1892

Published: 2017

Journal Articles

Blocking IL-21 signaling ameliorates xenogeneic GVHD induced by human lymphocytes

Keli L. Hippen, Christoph Bucher, Dawn K. Schirm, Amanda M. Bearl, Ty Brender, Kathy A. Mink, Kimberly S. Waggie, Regis Peffault de Latour, Anne Janin, Julie M. Curtsinger, Stacey R. Dillon, Jeffrey S. Miller, Gerard Socie, Bruce R. Blazar

Blood (2012) 119 (2): 619–628.

https://doi.org/10.1182/blood-2011-07-368027

Published: 2012

Includes: Supplemental data

Journal Articles

The murine equivalent of the A181E TACI mutation associated with common variable immunodeficiency severely impairs B-cell function

John J. Lee, Ingrid Rauter, Lilit Garibyan, Esra Ozcan, Tatyana Sannikova, Stacey R. Dillon, Anthony C. Cruz, Richard M. Siegel, Richard Bram, Haifa Jabara, Raif S. Geha

Blood (2009) 114 (11): 2254–2262.

https://doi.org/10.1182/blood-2008-11-189720

Published: 2009

Includes: Supplemental data

Journal Articles

A proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase–regulated mammalian target of rapamycin activation

Mamta Gupta, Stacey R. Dillon, Steven C. Ziesmer, Andrew L. Feldman, Thomas E. Witzig, Stephen M. Ansell, James R. Cerhan, Anne J. Novak

Blood (2009) 113 (21): 5206–5216.

https://doi.org/10.1182/blood-2008-09-179762

Published: 2009

Includes: Supplemental data

Journal Articles

APRIL-TACI Interactions Mediate Non-Hodgkin Lymphoma B Cell Proliferation through Akt Regulated Cyclin D1 and P21.

Mamta Gupta, PhD, Stephen M. Ansell, M.D./Ph.D., Thomas E. Witzig, M.D., Steven C. Ziesmer, James R. Cerhan, M.D., Stacey R. Dillon, Ph.D., Anne J. Novak, Ph.D.

Blood (2007) 110 (11): 3585.

https://doi.org/10.1182/blood.V110.11.3585.3585

Published: 2007

Journal Articles

Polymorphisms in the BLyS Gene Are Associated with an Increased Risk of Developing B-Cell Non-Hodgkin Lymphoma.

Anne J. Novak, Susan L. Slager, Steven C. Ziesmer, Alice H. Wang, James R. Cerhan, Stacey R. Dillon, Stephen M. Ansell

Blood (2007) 110 (11): 564.

https://doi.org/10.1182/blood.V110.11.564.564

Published: 2007

Journal Articles

Serum Cytokine Levels Predict Time to Progression after Rituximab as Initial Therapy in Patients with Follicular Grade 1 Non-Hodgkin Lymphoma.

Stephen M. Ansell, Anne J. Novak, Steven Ziesmer, Betsy LaPlant, James R. Cerhan, Zhi-Zhang Yang, Stacey R. Dillon, Thomas E. Witzig

Blood (2007) 110 (11): 3410.

https://doi.org/10.1182/blood.V110.11.3410.3410

Published: 2007

Journal Articles

Atacicept (TACI-Ig) Inhibits Growth of TACI high Primary Myeloma Cells in SCID-Hu Mice.

Shmuel Yaccoby, PhD, Stacey R. Dillon, PhD, Wen Ling, Paul Perkins, John R. Tisdale, Angela Pennisi, MD, Rinku Saha, Xin Li, PhD, Bart Barlogie, MD, PhD, Guido Tricot, MD, Fenghuang Zhan, MD, PhD, John Shaughnessy, PhD

Blood (2006) 108 (11): 842.

https://doi.org/10.1182/blood.V108.11.842.842

Published: 2006

Journal Articles

Splenic Sinusoids Stimulate the Survival and Proliferation of Hairy Cell Leukemia B Cells through BAFF, APRIL and Heparan-Sulphate Proteoglycans.

April Chiu, MD, Weifeng Xu, PhD, Bing He, Paul Santini, Stacey R. Dillon, PhD, Amy Chadburn, MD, Daniel M. Knowles, MD, Andrea Cerutti, MD

Blood (2006) 108 (11): 4959.

https://doi.org/10.1182/blood.V108.11.4959.4959

Published: 2006

Journal Articles

Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL

April Chiu, Weifeng Xu, Bing He, Stacey R. Dillon, Jane A. Gross, Eric Sievers, Xugang Qiao, Paul Santini, Elizabeth Hyjek, Joong-won Lee, Ethel Cesarman, Amy Chadburn, Daniel M. Knowles, Andrea Cerutti

Blood (2006) 109 (2): 729–739.

https://doi.org/10.1182/blood-2006-04-015958

Published: 2006

Journal Articles

B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenström macroglobulinemia

Sherine F. Elsawa, Anne J. Novak, Deanna M. Grote, Steven C. Ziesmer, Thomas E. Witzig, Robert A. Kyle, Stacey R. Dillon, Brandon Harder, Jane A. Gross, Stephen M. Ansell

Blood (2006) 107 (7): 2882–2888.

https://doi.org/10.1182/blood-2005-09-3552

Published: 2006

NARROW

Povetacicept (ALPN-303), a Potent Dual BAFF/APRIL Antagonist in Development for the Treatment of Autoimmune Cytopenias, Suppresses Disease in a Mouse Model of Autoimmune Hemolytic Anemia

A Randomized, Placebo-Controlled, Phase 1 Study in Healthy Adult Volunteers of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN303, a Potent Dual BAFF/APRIL Antagonist for the Treatment of Autoimmune Cytopenias

An Open Label Study of Alpn-101, a First-in-Class Dual CD28/ICOS Antagonist, in Subjects with Steroid-Resistant or Steroid-Refractory Acute Graft Versus Host Disease (aGVHD)

Therapeutic Candidate Alpn-101, a Dual ICOS/CD28 Antagonist, Potently Suppresses Human/NSG Mouse Xenograft Graft Vs. Host Disease (GvHD) in a Dose Ranging Study and Reduces Disease Activity in a Mouse Model of Hemophagocytic Lymphohistiocytosis (HLH)

Novel Variant Ig Domain (vIgD) Proteins Generated Via Directed Evolution of Igsf Domains Have Therapeutic Efficacy in Animal Models of Graft Versus Host Disease

Blocking IL-21 signaling ameliorates xenogeneic GVHD induced by human lymphocytes

The murine equivalent of the A181E TACI mutation associated with common variable immunodeficiency severely impairs B-cell function

A proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase–regulated mammalian target of rapamycin activation

APRIL-TACI Interactions Mediate Non-Hodgkin Lymphoma B Cell Proliferation through Akt Regulated Cyclin D1 and P21.

Polymorphisms in the BLyS Gene Are Associated with an Increased Risk of Developing B-Cell Non-Hodgkin Lymphoma.

Serum Cytokine Levels Predict Time to Progression after Rituximab as Initial Therapy in Patients with Follicular Grade 1 Non-Hodgkin Lymphoma.

Atacicept (TACI-Ig) Inhibits Growth of TACI high Primary Myeloma Cells in SCID-Hu Mice.

Splenic Sinusoids Stimulate the Survival and Proliferation of Hairy Cell Leukemia B Cells through BAFF, APRIL and Heparan-Sulphate Proteoglycans.

Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL

B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenström macroglobulinemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only